HIV treatment: latest news

HIV treatment resources

HIV treatment features

HIV treatment in your own words

HIV treatment news from aidsmap

More news

HIV treatment news selected from other sources

  • Early HIV treatment and isoniazid prophylaxis: why TEMPRANO results do not yet support universal ART at CD4 >500 cells/mm3

    The TEMPRANO study presented as a late breaker oral presentation, included important information for timing of TB prophylaxis and the timing of ART in TB-endemic countries. The conclusions though do not support universally starting treatment at CD4 counts >500 or answer the primary question of the international START study.

    03 March 2015 | HIV i-Base
  • Next-Generation HIV and Hep C Treatment Plans Ahead at CROI

    New research on the treatment and prevention of HIV/AIDS and hepatitis C will dominate the Conference on Retroviruses and Opportunistic Infections (CROI) 2015, which this year adds a special session on Ebola.

    13 February 2015 | Medscape (free registration required)
  • Dutrebis, New HIV Drug, Approved by FDA, but Not Commercially Available

    The new combination contains 150 mg of lamivudine (3TC, Epivir) and 300 mg of raltegravir (Isentress). Despite the FDA approval, the drug manufacturer, Merck Pharmaceuticals, announced that they would not be making Dutrebis commercially available in the U.S. at this time.

    11 February 2015 | The Body Pro
  • CROI 2015 Preview: New Research on HIV, Hepatitis C and Ebola

    It's the beginning of the year, which means another Conference on Retroviruses and Opportunistic Infections (CROI) is upon us. This year's CROI takes place in Seattle and should prove to be another exciting conference as new research is presented.

    11 February 2015 | The Body Pro
  • US: A Call for Improved HIV-Related Scientific Literacy on the Front Lines

    Poor scientific literacy among non-medical members of the HIV-related workforce must be addressed in order to better fight the epidemic. Many workers are unfamiliar with biomedical prevention of HIV—using antiretrovirals to reduce the risk of HIV transmission—and don’t know enough about how and when such an intervention should be used.

    10 February 2015 | AIDSMeds
  • Déjà Vu – Claims of HIV Cures and Re-Treading Old Ground

    A few days ago while in Abuja, I was surprised to hear the news presenter announce that a Federal High Court had “lifted the ban” on Dr Abalaka’s “vaccine” against HIV. I was struck by a number of things – an abiding discomfort at the quality of reporting on science and health matters in the Nigerian media; a sense of guilt that, in failing to tell our stories, younger Nigerians are at risk of repeating missteps of the past; and a fear that many, misled by the news item, may put their lives at risk.

    28 January 2015 | Nigeria Health Watch
  • Why scientific AIDS explanations struggle in townships

    HIV/AIDS educators often seem to enjoy raising an eyebrow at outlandish beliefs over the disease. But in doing so they fail to realise that the joke is on them – these ideas continue to hold sway despite their best efforts.

    26 January 2015 | Africa Check
  • Bill Gates Predicts Two Miracles for AIDS Relief by 2030

    Bill Gates said he expects a pair of advances by 2030 that will eliminate most of the damage from AIDS. Improved treatment and the development of a vaccine to prevent new infections are the “two miracles” needed to help turn the tide, the billionaire said Friday at the World Economic Forum in Davos, Switzerland.

    26 January 2015 | Bloomberg
  • Merck (MRK) Receives Positive CHMP Opinion for Dutrebis as HIV 1 Treatment

    On 22 January 2015, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Dutrebis, 150 mg lamivudine/300 mg raltegravir, film-coated tablet intended for the treatment of human immunodeficiency virus (HIV 1) infection in adults, adolescents, and children.

    26 January 2015 | Street Insider
  • Low CD4 count, suboptimal HIV treatment linked to higher anal cancer risk

    People with HIV who experienced extensive immune deficiency or who used early antiretroviral drugs before the advent of combination highly-active antiretroviral therapy (HAART) in the mid-90s may be at greater risk for developing anal cancer, according to a retrospective analysis published in the January 28 edition of AIDS.

    23 January 2015 |
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.